Anca Vasculitis - Pipeline Review, H1 2016

  • ID: 3674265
  • Report
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • GlaxoSmithKline Plc
  • Kineta, Inc.
  • MORE
Anca Vasculitis - Pipeline Review, H1 2016

Summary

‘Anca Vasculitis - Pipeline Review, H1 2016’, provides an overview of the Anca Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anca Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anca Vasculitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anca Vasculitis
- The report reviews pipeline therapeutics for Anca Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anca Vasculitis therapeutics and enlists all their major and minor projects
- The report assesses Anca Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anca Vasculitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anca Vasculitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anca Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • GlaxoSmithKline Plc
  • Kineta, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Anca Vasculitis Overview

Therapeutics Development

Pipeline Products for Anca Vasculitis - Overview

Anca Vasculitis - Therapeutics under Development by Companies

Anca Vasculitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Anca Vasculitis - Products under Development by Companies

Anca Vasculitis - Companies Involved in Therapeutics Development

ChemoCentryx, Inc.

GlaxoSmithKline Plc

Kineta, Inc.

Anca Vasculitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

belimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCX-1378 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCX-168 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Anca Vasculitis - Recent Pipeline Updates

Anca Vasculitis - Dormant Projects

Anca Vasculitis - Product Development Milestones

Featured News & Press Releases

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168

Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting

Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements

Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements

Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis

Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anca Vasculitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Anca Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016

Anca Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016

Anca Vasculitis - Pipeline by Kineta, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Anca Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016

Anca Vasculitis - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Anca Vasculitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
ChemoCentryx, Inc.
GlaxoSmithKline Plc
Kineta, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll